Erb Takes Root As Sunshine Heart CEO
This article was originally published in Clinica
Executive Summary
Heart failure device developer Sunshine Heart Inc. has appointed John Erb CEO, effective March 2. Erb had been filling in as interim CEO after the departure of former chief David Rosa in December. Rosa left amid the company’s struggles with the US pivotal trial for its C-Pulse system. Erb, who has more than 40 years of experience in medical device leadership and financial posts, has served as the director of Sunshine Heart since September 2012 and was named chairman in October 2012. He is a founder of NuAx Inc. – formerly Cardia Access Inc. – and from 2001 through 2006 he served as CEO of CHF Solutions Inc., which was acquired by Gambro Inc.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.